Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts-Reference-Cited by-同舟云学术

Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts

Published:2016-04 Issue:1 Volume:6 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Umeyama Kazuhiro,Watanabe Kota,Watanabe Masahito,Horiuchi Keisuke,Nakano Kazuaki,Kitashiro Masateru,Matsunari Hitomi,Kimura Tokuhiro,Arima Yoshimi,Sampetrean Oltea,Nagaya Masaki,Saito Masahiro,Saya Hideyuki,Kosaki Kenjiro,Nagashima Hiroshi,Matsumoto Morio

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep24413.pdf

Reference45 articles.

1. Sakai, L. Y., Keene, D. R. & Engvall, E. Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils. J Cell Biol 103, 2499–2509 (1986).

2. Robinson, P. N. & Booms, P. The molecular pathogenesis of the Marfan syndrome. Cell Mol Life Sci 58, 1698–1707 (2001).

3. Ramirez, F. & Dietz, H. C. Fibrillin-rich microfibrils: Structural determinants of morphogenetic and homeostatic events. J Cell Physiol 213, 326–330 (2007).

4. Neptune, E. R. et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33, 407–411 (2003).

5. Kaartinen, V. & Warburton, D. Fibrillin controls TGF-beta activation. Nat Genet 33, 331–332 (2003).

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regnase-1 overexpression as a therapeutic approach of Marfan syndrome;Molecular Therapy - Methods & Clinical Development;2024-03

2. Genetic models of fibrillinopathies;GENETICS;2023-11-16

3. Phenotypic features of dystrophin gene knockout pigs harboring a human artificial chromosome containing the entire dystrophin gene;Molecular Therapy - Nucleic Acids;2023-09

4. Genome Editing of Pig;Methods in Molecular Biology;2023

5. Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectives;MedComm;2022-07-14